Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (5): 1234-1242.doi: 10.13481/j.1671-587X.20230517

• Research in basic medicine • Previous Articles    

Inhibitory effect of silencing CDKL1 gene on proliferation and invasion of breast cancer MCF-7 cells by regulating PTEN/Akt/mTOR signaling pathway

Yuesheng ZHAO,Zubin LI,Haiou LIU,Kunlin TAO,Qihai ZHAO,Na LI()   

  1. Department of Breast Surgery,Third Affiliated Hospital,Qiqihar Medical College,Qiqihar City,Heilongjiang Province,Qiqihar 161000,China
  • Received:2022-10-14 Online:2023-09-28 Published:2023-10-26
  • Contact: Na LI E-mail:loyse2279@163.com

Abstract:

Objective To discuss the effect of cell division cyclin-dependentkinase like-1 (CDKL1) gene silencing on the proliferation, invasion, and metastasis of the breast cancer MCF-7 cells, and to clarify its possible mechanism. Methods The breast cancer MCF-7 cells were used as the research subjects, and the small interfering RNA (siRNA) technology was used to silence the expression of the CDKL1 gene. The intervention was performed by using 1 μmol·L-1 phosphatase and tension homolog (PTEN) inhibitor BpV or 10 μmol·L-1 protein kinase B(Akt) agonist SC79. The MCF-7 cells at logarithmic growth phase were divided into control group (MCF-7 cells without any treatment), transfection control (siRNA-NC) group (MCF-7 cells transfected with siRNA-NC plasmid), siRNA-CDKL1 group (MCF-7 cells transfected with siRNA-CDKL1 plasmid), siRNA-CDKL1+BpV group (MCF-7 cells transfected with siRNA-CDKL1 and treated with 1 μmol·L-1 PTEN inhibitor BpV for 2 h), and siRNA-CDKL1+SC79 group (MCF-7 cells transfected with siRNA-CDKL1 and treated with 10 μmol·L-1 Akt agonist SC79 for 2 h). Real-time fluorescence quantitative PCR (RT-qPCR) and Western blotting methods were used to detect the expression levels of CDKL1 mRNA and protein in the breast cancer MCF-7 cells in various groups; CCK-8 assay was used to detect the proliferation activities of the breast cancer MCF-7 cells in various groups;EdU assay was used to detect the rates of EdU positive cells in the breast cancer MCF-7 cells in various groups;cell scratch healing experiment was used to detect the scratch healing rates of the breast cancer MCF-7 cells in various groups; Transwell chamber assay was used to detect the numbers of migration and invasion breast cancer MCF-7 cells in various groups;Western blotting method was used to detect the expression levels of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), PTEN, Akt, mammalian target of rapamycin (mTOR), phosphorylated Akt (p-Akt), and phosphorylated mTOR (p-mTOR) proteins in the breast cancer MCF-7 cells in various groups. Results Compared with siRNA-NC group, the expression levels of CDKL1 mRNA and protein in the breast cancer MCF-7 cells in siRNA-CDKL1 group were decreased (P<0.01), the proliferation activity was decreased(P<0.01),the rate of EdU positive cells was decreased(P<0.01),and the numbers of migration and invasion cells were decreased (P<0.01), the expression levels of MMP-2, MMP-9, p-Akt, and p-mTOR proteins in the cells were decreased (P<0.01), and the expression level of PTEN protein was increased (P<0.01). Compared with siRNA-CDKL1 group, the proliferation activities of the breast cancer MCF-7 cells in siRNA-CDKL1+BpV group and siRNA-CDKL1+SC79 group were increased (P<0.01),the rate of EdU-positive cells was increased(P<0.01), the numbers of migration and invasion cells were increased(P<0.01), the expression levels of MMP-2, MMP-9, p-Akt, and p-mTOR proteins in the cells were increased(P<0.01),and the expression level of PTEN protein in the cells was decreased (P<0.01). Conclusion Silencing CDKL1 gene can inhibit the proliferation, invasion,and metastasis abilities of the breast cancer MCF-7 cells, and its mechanism may be related to the regulation of the PTEN/Akt/mTOR signaling pathway.

Key words: Breast neoplasm, Cyclin-dependentkinase like-1, Phosphatase and tension homolog, Protein kinase, Mammalian target of rapamycin, Cell proliferation, Cell migration, Cell invasion

CLC Number: 

  • R737.9